Latest News
FDA Approves Wilserdly (giredestrant) for ER-Positive, ESR1-Mutated Advanced Breast Cancer
South San Francisco, CA -- November 16, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the United States (U.S.) Food and Drug Administration (FDA) ha
FDA Approves Klygefa (gefurulimab) for the Treatment of Generalised Myasthenia Gravis
16 November 2026 -- Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetyl
FDA Approves Pebrilzo (pertuzumab-qcay), a Biosimilar to Perjeta
BENGALURU, India and BRIDGEWATER, N.J., United States: November 16, 2026 -- Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced that the U.S.
FDA Approves Pimjetmi (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor
November 10, 2026 -- EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved Pimjetmi
FDA Approves Sunharbo (asundexian) in Combination with Antiplatelet Therapy for Secondary Stroke Prevention
WHIPPANY, N.J.-- November 9, 2026 -- Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
PLYMOUTH MEETING, Pa., Oct. 30, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel
FDA Approves Lucamzi (ranibizumab-blrz), a Biosimilar to Lucentis
Solna, Sweden 27 October 2026 -- Lucamzi™ (ranibizumab-blrz) biosimilar to Lucentis® has been approved by FDA in the US. Xbrane will finalize preparation for an upcoming launch of the product during 2
FDA Approves Hibsago (bepirovirsen) for the Treatment of Chronic Hepatitis B
London, UK -- 20 October 2026 -- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CH
FDA Approves Brytly (apraclonidine) Ophthalmic Solution for Relief of Eye Redness
GENEVA--(BUSINESS WIRE) October 16, 2026 -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that the U.S. Food and Drug Administration
FDA Approves Hovilpri (pritelivir) for the Treatment of Mucocutaneous Herpes Simplex Virus (HSV) Lesions
Tokyo – October 10, 2026 -- Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolin
FDA Approves Weltruza (olanzapine) Once-Monthly Subcutaneous Injection for the Treatment of Adults with Schizophrenia
PARSIPPANY, N.J. and TEL AVIV, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.
FDA Approves Emcitate (tiratricol) for the Treatment of Patients with MCT8 Deficiency
STOCKHOLM, SWEDEN, Sept. 28 2026. (GLOBE NEWSWIRE) -- Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug
News
- CanalLotus Biotech -
Int'l Clinical Service Expert
We are the leader
Because of our professionism











